By releasing PRF1, GNLY, or GZM and rupturing previous immunological tolerance, CD8 + T cells can destroy cancer cells and improve immunotherapy by activating the PD-1/PD-L1 immune inhibitory axis. The gene discussed is CD8A; the disease is cancer.